| 44th week of 2010 patent applcation highlights part 36 |
| Patent application number | Title | Published |
|---|
| 20100278837 | Compositions And Methods For Reducing Cancer And Inflammation - This invention relates to the discovery of the convergence of diverse receptors and signaling pathways on the PI3gamma dependent activation of VLA4 (integrin a4b1). In particular, the invention relates to the role of myeloid cells in tumor inflammation and metastasis. The invention provides methods for inhibiting cancer in a subject comprising administering to a subject having cancer that comprises endothelial cells a therapeutically effective amount of a PI-3-kinase gamma inhibitor that reduces at least one of (a) adhesion of myeloid cells to the endothelial cells, (b) migration of myeloid cells into the cancer, (c) growth of the cancer, (d) activation of integrin a4b1 that is comprised on the myeloid cells, and (e) clustering of integrin a4b1 that is comprised on the myeloid cells. | 2010-11-04 |
| 20100278838 | EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K | 2010-11-04 |
| 20100278839 | ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY - The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided. | 2010-11-04 |
| 20100278840 | METHODS FOR TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS - A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed. | 2010-11-04 |
| 20100278841 | DOWN-REGULATION OF MORTALIN BY siRNA - Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed. | 2010-11-04 |
| 20100278842 | ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates. | 2010-11-04 |
| 20100278843 | AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY - The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1). | 2010-11-04 |
| 20100278844 | Cancer Marker and Therapeutic Target - Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents. | 2010-11-04 |
| 20100278845 | Melanocortin Receptor Binding Conjugates - The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing. | 2010-11-04 |
| 20100278846 | NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT SEQUENCES - Multiple sequential screening tests have been performed on phage display libraries, and polypeptide sequences have been identified that potently drive both: (i) intake into mucosal immune cells, including NALT cells in the nose and throat; and, (ii) phagocytic intake and processing by antigen-presenting cells, such as macrophages. Such polypeptide sequences can be used as potent “target and deliver” components in vaccines that can be administered nasally, or to other mucous membranes. Such vaccines can be made very rapidly and in huge quantities, from bacteriophages that will also carry antigenic sequences in their coat proteins, or other immunoactive components. Alternately, such “target and deliver” polypeptides can be incorporated into vaccines derived from eukaryotic viruses or cellular pathogens. Enhancements also are disclosed, such as agents that can activate one or more types of toll-like receptors, to increase immunes responses and guide them in desired directions. | 2010-11-04 |
| 20100278847 | MUTUALLY SUPPRESSIVE GENE/INHIBITOR COMBINATIONS FOR NON-ANTIBIOTIC SELECTION OF RECOMBINANT STRAINS - This invention relates to vector sequences that express growth inhibitory levels of essential genes used in combination with inhibitors that target the same gene. An example given is the use of the gene encoding the fatty acid biosynthesis enzyme enoyl-ACP reductase used in combination with the antimicrobial triclosan. The expression level of the enoyl-ACP reductase is sufficient to suppress the toxic effects of triclosan and the triclosan is used at levels that are sufficient to suppress the toxic effects of the enoyl-ACP reductase. The invention provides methods to enhance the growth and survival of genetically modified organisms and to increase the production and expression of plasmid vectors in the presence of triclosan, relative to methods that rely on antibiotics and antibiotic resistance markers. Also, the invention provides methods to limit the spread of genetically modified organisms. The vectors and methods are useful to avoid the use of antibiotics and antibiotic markers, to contain genetically modified organisms and to increase the production of recombinant material or metabolites from host organisms. | 2010-11-04 |
| 20100278848 | TUMOR ANTIGEN BFY3 FOR PREVENTION AND/OR TREATMENT OF CANCER - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. | 2010-11-04 |
| 20100278849 | PROSTATIC ACID PHOSPHATASE ANTIGENS - The invention relates to peptides from Prostatic Acid Phosphatase (PAP), especially those identified as PAP.135 and PAP.161. The nucleic acid molecules encoding the peptides, antibodies against the peptides, and the use of such peptides, nucleic acids and antibodies in immunotherapy, vaccines and assays are also included in the scope of the invention. | 2010-11-04 |
| 20100278850 | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof - The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention. | 2010-11-04 |
| 20100278851 | CTL INDUCER COMPOSITION - The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group. | 2010-11-04 |
| 20100278852 | ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 2010-11-04 |
| 20100278853 | CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS - The present invention provides constrained peptides and other organic molecules, that mimic the three dimensional characteristics of the HIV-1 V3 loop peptide when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope, which structure is determined by NMR. Methods for screening for, and designing such molecules are disclosed. These molecules are useful as immunogens for inducing broadly-neutralizing antibodies against HIV-1 as well as antagonists for inhibiting the binding of HIV-1 to the relevant co-receptors, and may therefore be used in method of preventing or treating HIV-1 infection and disease. | 2010-11-04 |
| 20100278854 | CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as | 2010-11-04 |
| 20100278855 | NEUROPROTECTIVE GANODERMA COMPOSITIONS AND METHODS OF USE - The subject invention provides methods for treatment of degenerative neurological disorders such as Parkinson's disease and Alzheimer's disease comprising administration of a | 2010-11-04 |
| 20100278856 | BoNT/A PEPTIDES AND METHODSOF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY - The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. | 2010-11-04 |
| 20100278857 | Dendritic Cell Binding Proteins and Uses Thereof - The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided. | 2010-11-04 |
| 20100278858 | PROCESS FOR PREPARING ATTENUATED VIRAL STRAINS - Provided is a process for preparing attenuated viral strains, comprising to contact, at least one sulphated polymer and a virus susceptible to the inhibition of the polymer, via successive passages of the virus with increasing polymeric concentrations, where the amenable virus is characterized by the method of reducing viral plates and where the strain resulting from the attenuated virus has stable phenotypic and genotypic characteristics, different from that of the virus strain in wild state that generated thereto. The process comprises to contact the sulphated polymer(s) with the virus susceptible to the inhibition of the polymer via about 15 or more successive passages with increasing concentrations of the sulphated polymer(s). According to the inventive process, the concentration of the at least one sulphated polymer in the first passage should be less than the IC | 2010-11-04 |
| 20100278859 | DIAGNOSTIC TEST KITS - This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection. | 2010-11-04 |
| 20100278860 | SYSTEM AND METHOD FOR IDENTIFYING COMPLEX PATTERNS OF AMINO ACIDS - A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries, embodiments of the present invention may scan the received protein descriptions to identify and locate Replikin patterns. A Replikin pattern is defined to be a sequence of 7 to about 50 amino acids that include the following three (3) characteristics, each of which may be recognized by an embodiment of the present invention: (1) the sequence has at least one lysine residue located six to ten amino acid residues from a second lysine residue; (2) the sequence has at least one histidine residue; and (3) at least 6% of the amino acids in the sequence are lysine residues. | 2010-11-04 |
| 20100278861 | METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS - The instant invention provides methods for determining, predicting and characterizing the genetic variability, emergence and expansion of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens. | 2010-11-04 |
| 20100278862 | Nipah Virus Vaccines - The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene. | 2010-11-04 |
| 20100278863 | Reoviruses - The present invention provides a reverse genetics system for viruses belonging to the Reoviridae (i.e. Reoviruses), various uses thereof, genetically modified Reoviruses, Reovirus selection/production and propagation systems, medicaments and vaccines. | 2010-11-04 |
| 20100278864 | Rabies Vaccine - An attenuated rabies virus for use as a live vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the live vaccine. | 2010-11-04 |
| 20100278865 | PRODUCTION AND USE OF EPITOPE-TAGGED HEPATITIS C VIRUS PARTICLE - This invention relates to a nucleic acid comprising a nucleic acid sequence encoding an epitope tag peptide in the hypervariable region 1 of the E2 protein of naturally occurring or chimeric hepatitis C virus (HCV) genome, an epitope-tagged HCV particle encoded by such nucleic acid, and a method for purifying the HCV particles at a high purity in a simple manner with the use of an anti-epitope tag antibody-immobilized support. | 2010-11-04 |
| 20100278866 | BORRELIA DIAGNOSTICS AND SCREENING METHODS - Compositions and methods of detecting | 2010-11-04 |
| 20100278867 | Use of botulinum toxin for the treatment of chronic facial pain - The present invention includes a method of treating pain caused by neuralgia comprising administering botulinum toxin to an afflicted area of a patient. The pain may be caused by trigeminal neuralgia or be associated with dental extraction or reconstruction, and may be facial pain. The neuralgia may be associated with compressive forces on a sensory nerve, intrinsic nerve damage, demyelinating disease, a genetic disorder, a metabolic disorder, central neurologic vascular disease, or trauma. The present invention also includes a method of treating post-operative incisional wound pain comprising administering botulinum toxin to an afflicted area of a patient. The post-operative incisional wound pain may be associated with medical treatments selected from the group consisting of sinus surgery, removal of an eye, temporal mandibular joint surgery, parotid gland extraction and resection, craniotomy for removal of an intracranial tumor, intra-ocular surgery, acoustic neuroma surgery, reconstructive procedures after tumor resection, radiation therapy for the treatment of cancer, skull base surgery, orbitectomy, facial bone removal, muscle removal, skin removal, and construction of myocutaneous flaps. | 2010-11-04 |
| 20100278868 | Codon-Optimized Dna Molecules Encoding the Receptor Binding Domains of Clostridium Difficile Toxins A and B, and Methods of Use Thereof - In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of | 2010-11-04 |
| 20100278869 | Plant Produced Vaccine for Amebiasis - Disclosed herein are methods of making a vaccine against | 2010-11-04 |
| 20100278870 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a | 2010-11-04 |
| 20100278871 | ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN - Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors. | 2010-11-04 |
| 20100278872 | MEDICAMENTS AND METHODS FOR TREATING MESOTHELIOMA - The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual. | 2010-11-04 |
| 20100278873 | STIMULATION OF ANTI-TUMOR IMMUNITY USING DENDRITIC CELL/TUMOR CELL FUSIONS AND ANTI-CD3/CD28 - The invention is concerned with fusions of dendritic cells and with tumor or cancer cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy as well as methods of stimulating anti-tumor immunity using fused cells and anti-CD3/CD28 antibodies. | 2010-11-04 |
| 20100278874 | REAGENTS AND METHODS FOR CANCER TREATMENT AND PREVENTION - The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects. | 2010-11-04 |
| 20100278875 | PROSTAGLANDIN E2 (PGE2) AS AN ADJUVANT IN MONOCLONAL ANTIBODY GENERATION - The present invention provides PGE2 as a novel adjuvant for enhancing the immune response in a host, as well as methods of using PGE2 to enhance B cell response and thereby increasing antibody titer against a given immunogen are also disclosed and antibodies produced by at least one method of the present invention. | 2010-11-04 |
| 20100278876 | HIGH-SOLID ANTIFOULING PAINT COMPOSITION, ANTIFOULING COATING FILM, BASE MATERIAL WITH COATING FILM, ANTIFOULING BASE MATERIAL, METHOD FOR FORMING COATING FILM ON SURFACE OF BASE MATERIAL, ANTIFOULING METHOD FOR BASE MATERIAL, AND HIGH-SOLID MULTI-PACKAGE ANTIFOULING PAINT COMPOSITION SET - Disclosed is a high-solid antifouling paint composition characterized by including:
| 2010-11-04 |
| 20100278877 | BODY TISSUE FILLING MATERIAL AND METHOD FOR PRODUCTION THEREOF - There are provided a body tissue filling material having excellent engraftability and repairability, and a method for producing such a body tissue filling material in a simple manner. Specifically disclosed are: a body tissue filling material comprising a gelatin porous carrier, to the surface of which a coating having sulfated hyaluronic acid is applied; and a method for producing a body tissue filling material, comprising: a step (S | 2010-11-04 |
| 20100278878 | QUETIAPINE SALTS AND THEIR POLYMORPHS - The present invention relates to novel and stable salt forms of quetiapine, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides novel acid addition salts of quetiapine wherein the acid counter ion is provided by an acid selected from the group consisting of benzene sulfonic acid, dibenzoyl-L-(+)-tartaric acid and di-p-toluoyl-L-(+)-tartaric acid. The present invention also provides novel polymorphic forms of quetiapine salts selected from the group consisting of quetiapine hydrobromide, quetiapine sulfate, quetiapine nitrate and quetiapine citrate. | 2010-11-04 |
| 20100278879 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2010-11-04 |
| 20100278880 | PHARMACEUTICAL FORMULATION FOR ALLERGEN PREPARATION - Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract or a method for the production of a purified extract of natural allergens comprising the steps of hydrolysing a denaturated allergen purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da, in the form of an starch based pellet. | 2010-11-04 |
| 20100278881 | USE OF CALCITONIN IN OSTEOARTHRITIS - The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans. | 2010-11-04 |
| 20100278882 | USE OF PROTEIN MICROBEADS IN COSMETICS - Use of protein microbeads in cosmetics | 2010-11-04 |
| 20100278883 | USE OF AMPHIPHILIC SELF-ASSEMBLING PROTEINS FOR FORMULATING POORLY WATER-SOLUBLE EFFECT SUBSTANCES - The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances. | 2010-11-04 |
| 20100278884 | Skin cosmetics comprising cocoon-shaped polymer fine particles - Previously proposed skin cosmetics have been compounded with spherical resin particles for the purpose of improving extendability on the skin, improving feel, and making fine wrinkles unnoticeable. However, these particles are insufficient in their effect of making fine wrinkles on the skin unnoticeable, and there has been demand for fine particles that let the skin appear smooth and fair. | 2010-11-04 |
| 20100278885 | C70-Containing Liposome, Method for Producing the Same, and Use of the Same - A solution containing a C | 2010-11-04 |
| 20100278886 | PERSONAL CARE DISSOLVABLE FILMS - Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and detackifying agent are described, along with methods of using the same. | 2010-11-04 |
| 20100278887 | Use of a Haemoglobin for the Preparation of Dressings and Resulting Dressings - The invention relates to the use of a haemoglobin for the preparation of dressings and to the resulting dressings. | 2010-11-04 |
| 20100278888 | COMPOSITION FOR COSMETIC RAW MATERIAL CONTAINING CELLULOSE DYED WITH NATURAL COLORING MATTER HAVING IMPROVED PHOTOSTABILITY, AND VISUAL CARRIER SYSTEM COMPRISING THE SAME - The present invention relates to a composition for cosmetic raw material containing cellulose dyed with a natural coloring matter having improved photostability, and a visual carrier system comprising the same. In the composition for cosmetic raw material and the visual carrier system comprising the same according to the present invention, by using no iron oxide chemical coloring matter and applying a typical and natural dyeing method of cloths to the microcrystalline cellulose that is the cosmetic raw material, photostability that is a problem of the natural coloring matter in the related art is largely improved. | 2010-11-04 |
| 20100278889 | COMPOSITIONS HAVING SUSTAINED-RELEASE INSECT REPELLENCY - The present invention pertains to the field of clay compositions, and to tick- or insect-repellent compositions containing clay, particularly to tick- or insect-repellant formulations comprising dihydronepetalactone, a nepetalactam, a dihydronepetalactam and/or their respective derivatives and clay that provide sustained release to improve utilization of the active ingredient and require less-frequent renewal. | 2010-11-04 |
| 20100278890 | Use of Lignosulfonates in Suspo-emulsions for Producing Pesticide Compositions - Disclosed are compositions and methods related to powder and granular concentrate pesticide formulations. As disclosed, suspo-emulsions comprising pesticide actives may be prepared using a high purity, high molecular weight lignosulfonate as a stabilizer. The resulting suspo-emulsions may then be dried to obtain a powder or granular concentrate where the high molecular weight lignosulfonate acts as a solid matrix for the pesticide actives. The powder or granular concentrate formulations thus formed have high loading rates, good storage properties and are easily reconstituted when added to water. | 2010-11-04 |
| 20100278891 | BI-PHASIC COMPRESSED POROUS REINFORCEMENT MATERIALS SUITABLE FOR IMPLANT - A high strength porous biphasic polymeric reinforcement material manufactured by a compression and/or sintering process is disclosed. The material results in a network of interconnected collapsed pores, which forces thin overlapping walls and passages to be created. The network provides permeable access for fluid migration throughout the material. The strength and/or permeability are advantageous for medical devices and implants. | 2010-11-04 |
| 20100278892 | HIGH AFFINITY METAL-OXIDE BINDING PEPTIDES WITH REVERSIBLE BINDING - A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, in mechanical, biomechanical, micro fluidic, electronic, bioelectronic, bio-optical, and biochemical devices. Experiments were carried out to assess functionalization and reusability of a suspended mass resonator's cantilever. | 2010-11-04 |
| 20100278893 | IMPLANTABLE MATERIAL COMPRISING CELLULOSE AND THE GLYCOPEPTIDE XYLOGLUCAN-GRGDS - Implantable materials for medical or surgical applications comprising specific chemical groups on their surface to alter the physico-chemical properties of said material rendering it suitable implantation or biocompatible properties. | 2010-11-04 |
| 20100278894 | ANTIOXIDANTS AND ANTIMICROBIAL ACCESSORIES INCLUDING ANTIOXIDANTS - An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer. The antimicrobial accessory may also include a topcoat formed on the sacrificial diffusion layer. The topcoat may include a biodegradable polymer and at least one antioxidant mixed in the biodegradable polymer. | 2010-11-04 |
| 20100278895 | ANTIOXIDANTS AND ANTIMICROBIAL ACCESSORIES INCLUDING ANTIOXIDANTS - An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer. The antimicrobial accessory may also include a topcoat formed on the sacrificial diffusion layer. The topcoat may include a biodegradable polymer and at least one antioxidant mixed in the biodegradable polymer. | 2010-11-04 |
| 20100278896 | SOLID COMPOSITIONS - A solid, implantable dosage form comprising a therapeutically active agent in solid form, optionally with one or more pharmaceutically acceptable excipients, wherein the one or more excipients, when present, do not lead to a significant delay or prolongation of the release of active agent, as compared to an equivalent dosage form containing no excipients when tested in vitro. | 2010-11-04 |
| 20100278897 | INTRAOCULAR BIOACTIVE AGENT DELIVERY SYSTEM WITH MOLECULAR PARTITIONING SYSTEM - The present disclosure generally provides intraocular implants including at least one therapeutic bioactive agent and a molecular partitioning system. The molecular partitioning system comprises at least two phases wherein the first phase has an inherent viscosity equal or greater than the inherent viscosity of a second phase. The molecular partitioning system allows the intraocular implants to controllably release the at least one therapeutic bioactive agent into the surrounding tissues once implanted. | 2010-11-04 |
| 20100278898 | INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS - The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal. | 2010-11-04 |
| 20100278899 | EDIBLE FILM - An edible film to be ingested from an oral cavity of a living body to a body thereof is provided. The edible film is comprised of a laminated body consisting of a plurality of layers. The laminated body has surfaces and the plurality of layers include two surface layers forming of the surfaces of the laminated body. At least one of the two surface layers is disposed as an antiadhesive layer for preventing the edible film from adhering to an inside wall of the oral cavity by dissolving with water. This edible film is a film that it is difficult to adhere to the inside wall of the oral cavity, and even if it adheres to the inside wall, it is possible to easily peel off the edible film therefrom. | 2010-11-04 |
| 20100278900 | CHLORINE DIOXIDE BASED GUM AND CANDY - Provided are oral compositions and devices comprising an active agent that is one of chlorine dioxide-generating components, a chlorine dioxide-containing solution, and combinations thereof. | 2010-11-04 |
| 20100278901 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS - The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth. | 2010-11-04 |
| 20100278902 | STRONTIUM DOPED BIOACTIVE GLASSES - The invention relates to bioactive glasses containing or doped with strontium, to a method for preparing the same and to the use thereof in methods for bone repair or reconstruction. | 2010-11-04 |
| 20100278903 | PROPHYLACTIC AND IMMUNOMODULATORY COMPOSITIONS AND USES - Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of an immunomodulation medicament effective in the prevention of infectious disease and treatment and/or prevention of an autoimmune disease. | 2010-11-04 |
| 20100278904 | NUCLEOTIDE VACCINE - The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The vaccine stimulates an immune response, especially an immune response in an MHC-I dependent, but CD4 | 2010-11-04 |
| 20100278905 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2010-11-04 |
| 20100278906 | MOISTURIZING ANTIMICROBIAL COMPOSITION - An antimicrobial moisturizing composition includes benzethonium chloride or benzalkonium chloride, a non-benzyl cationic surfactant, and an aqueous carrier. The composition of the present invention provides a significant and unexpected reduction of irritation, inflammation, dryness and/or redness, all issues associated with known alcohol-based skin disinfectants. In particular, the present invention provides a stable, aesthetically-pleasing, long-lasting, and moisturizing antimicrobial composition that is substantially free of ethanol, polysorbates, and anionic compounds that are known to inhibit the activity of benzethonium chloride or benzalkonium chloride. | 2010-11-04 |
| 20100278907 | Immunogenic Compositions Containing Ceramide and Methods of Use Thereof - Immunogenic compositions containing ceramide or ceramide analogs for treating or reducing the risk of developing one or more symptoms of a disease or disorder associated with ceramide-induced cell death are provided. The immunogenic compositions contain immunogenic ceramide, and, optionally, pharmaceutically acceptable excipients and one or more additional adjuvants. Methods of using the disclosed immunogenic ceramide compositions for reducing ceramide-induced cell death are provided. Methods of using the disclosed immunogenic ceramide compositions therapeutically or prophylactically for treating or reducing the risk of developing one or more symptoms of a disease or disorder associated with ceramide-induced cell death are also provided. | 2010-11-04 |
| 20100278908 | COMPOSITIONS INCORPORATING AGENTS FOR REDUCING CELLULITE AND UNAESTHETIC APPEARANCE ASSOCIATED THEREWITH AND FORMULATIONS CONTAINING THEM - The present invention relates to synergic compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith which comprise a base matrix constituted by conjugated linoleic acid (CLA), grape seed extract, beta-glucan, organic calcium and dry extract of pine bark together with complementary synergic agents of the matrix. The invention also relates to the use of such compositions and formulations containing said compositions. | 2010-11-04 |
| 20100278909 | PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS - A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules. | 2010-11-04 |
| 20100278910 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 2010-11-04 |
| 20100278911 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 2010-11-04 |
| 20100278912 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate. | 2010-11-04 |
| 20100278913 | CHEWABLE TABLET - An excipient base for a chewable tablet comprising xylitol, sucralose and microcrystalline cellulose. The excipient base provides for an improved taste, stabilization, and mouthfeel qualities for the chewable tablet, as well as a greater likelihood for dosage compliance and use. The excipient base also enables the tablet to be directly compressible, free flowing and non-tacky, thus avoiding wet granulation techniques that can degrade the product and add to the cost of the manufacturing process. The excipient base also allows for the production of a chewable tablet that is suitable for administration to persons and animals having diabetes or hypoglycemia, and does not promote tooth decay or dental caries. | 2010-11-04 |
| 20100278914 | FRACTION OF MELISSA LEAF EXTRACT HAVING ANGIOGENESIS AND MMP INHIBITORY ACTIVITIES, AND COMPOSITION COMPRISING THE SAME - The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same. | 2010-11-04 |
| 20100278915 | COMPOSITIONS COMPRISING AN ANTIHISTAMINE, ANTITUSSIVE AND DECONGESTANT IN EXTENDED RELEASE FORMULATIONS - The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant. | 2010-11-04 |
| 20100278916 | TOPICAL APPLICATION AND FORMULATION OF ERYTHROPOIETIN FOR SKIN WOUND HEALING - The invention relates to the use of erythropoietin (EPO), in particular EPO in a polymer-based pharmaceutical preparation which stabilises the active compound, for the treatment of traumatised skin, in particular for wound healing in the case of mechanical or pathological injuries or in the case of burns. | 2010-11-04 |
| 20100278917 | Formulations and Methods of Treating Inflammatory Bowel Disease - Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis. | 2010-11-04 |
| 20100278918 | EXTENDED RELEASE FORMULATION OF NEVIRAPINE - The invention relates to an extended release pharmaceutical composition comprising nevirapine. | 2010-11-04 |
| 20100278919 | Dendritic cell targeting compositions and uses thereof - The present invention provides compositions and methods for targeting dendritic cells of the immune system. In particular, the compositions comprise carbon nanoparticles, optionally magnetic carbon nanoparticles comprising iron, which are preferentially endocytosed by dendritic cells compared to macrophages when contacted with a biological sample. The nanoparticles of the present invention may be functionalized to enhance delivery of biomolecules to dendritic cells. | 2010-11-04 |
| 20100278920 | Polyacrylate Nanoparticle Drug Delivery - Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax. | 2010-11-04 |
| 20100278921 | SOLID ORAL FORMULATION OF ABT-263 - An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2010-11-04 |
| 20100278922 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN - The present invention provides a pharmaceutical composition formulated for oral delivery of insulin, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and insulin suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of insulin. | 2010-11-04 |
| 20100278923 | Functional nanoparticle-based antibiotics and preparation method thereof - The present invention is related to a novel functional nanoparticle-based antibiotics and preparation method thereof, especially related to an antibiotics-modified nanoparticle. The functional nanoparticle-based antibiotics according to the present invention can be used as the affinity probes and the photothermal agents to effectively inhibit the cell growth of pathogenic bacteria under NIR irradiation. | 2010-11-04 |
| 20100278924 | Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents - Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties. | 2010-11-04 |
| 20100278925 | FORMULATIONS OF ORGANO-PLATINIC COMPOUNDS IN THE PRESENCE OF ASSOCIATIVE POLYMERS, PRODUCTS THUS OBTAINED AND USES THEREOF - The invention consists of formulations based on compounds of platinum encapsulated by associative and water-soluble polymers. These formulations are in aqueous form or in the form of granulates. The invention further pertains to pharmaceutical preparations which contain these formulations, and their implementation in the fabrication of an orally administered medication, in polychemotherapy treatments. | 2010-11-04 |
| 20100278926 | Controlled Release Oral Dosage Form - A once a day bupropion salt formulation is disclosed. | 2010-11-04 |
| 20100278927 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION - The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 2010-11-04 |
| 20100278928 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER - The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 2010-11-04 |
| 20100278929 | ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES - The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention. | 2010-11-04 |
| 20100278930 | ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME - The invention provides an orally disintegrating tablet containing (a) one or more saccharides or sugar alcohols selected from the group consisting of mannitol, lactose, xylitol, sucrose, erythritol and glucose and (b) low substituted hydroxypropylcellulose and substantially free of a starch disintegrant, which tablet is produced by steps of granulating a composition containing the above-mentioned components (a) and (b) by an agitation granulation method, and compression-molding the obtained granulation product. The invention also provides a method of producing an orally disintegrating tablet substantially free of a starch disintegrant, including steps of granulating a composition containing the above-mentioned components by an agitation granulation method, and compression-molding the obtained granulation product. | 2010-11-04 |
| 20100278931 | POROUS SILICON DRUG-ELUTING PARTICLES - The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents | 2010-11-04 |
| 20100278932 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER - The present invention provides micelles having SN-38 encapsulated therein. | 2010-11-04 |
| 20100278933 | KINASE INHIBITOR COMPOUNDS - The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer. | 2010-11-04 |
| 20100278934 | METHODS AND COMPOSITIONS FOR CONSERVING AND/OR PREPARING AN ORGAN OR TISSUE FOR TRANSPLANT - A method of conserving and/or preparing an organ or tissue for transplant for a subject, includes administering to a subject, organ or tissue in need of such treatment an effective amount of a composition including a polypeptide agent including thymosin beta 4 (TB4), an isoform, analogue or derivative of TB4 having biological activity of TB4, an N-terminal variant of TB4 having biological activity of TB4, a C-terminal variant of TB4 having biological activity of TB4, LKKTET or a conservative variant thereof, LKKTNT or a conservative variant thereof, KLKKTET or a conservative variant thereof, LKKTETQ or a conservative variant thereof, TB4 sulfoxide, TB4ala, TB9, TB10, TB11, TB12, TB13, TB14, TB15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ?-actinin or acumentin, or a stimulating agent that stimulates production of a polypeptide agent as described above, or a conservative variant thereof, in the organ or tissue. | 2010-11-04 |
| 20100278935 | Immune System Modulator Formulation - Compositions and methods for treating and/or preventing a medical condition are provided. For example, in one aspect the present invention provides a composition for treating or preventing a medical condition in a subject. Such a composition may include a sodium phosphate compound, an ammonium compound, and a silicate compound. Such a composition may be formulated for a variety of administrations modes, including, without limitation, oral, intramuscular, intravenous, transdermal, buccal, etc. | 2010-11-04 |
| 20100278936 | COMPOSITION FOR TREATING SKIN LESIONS - The present invention provides a composition for topical treatment of skin and mucosal membrane lesions comprising a synergistic combination of copper compound and hypericum perforatum extract. | 2010-11-04 |
